Clinical Trials Logo

Clinical Trial Summary

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of LCAR-B38M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).


Clinical Trial Description

Multiple myeloma (MM) is a usually incurable malignancy of plasma cells. Current therapies for multiple myeloma often cause remissions, but nearly all patients eventually relapse and die, an clear unmet clinical needs. As early as mid-2014, the investigators have started to develop a series of proprietary CAR-T products to target B cell maturation antigen (BCMA), a cell surface molecule which the investigator believes to be a desirable target antigen for multiple myeloma. All pre-clinical data and CMC data for LCAR-B38M CAR-T cell technology has been established by mid-2015 and a phase I proof-of-concept clinical trial has been planned since then. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03090659
Study type Interventional
Source Nanjing Legend Biotech Co.
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date October 2, 2015
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03380039 - Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma N/A
Active, not recruiting NCT03716856 - Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma Phase 1
Active, not recruiting NCT03674463 - LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma Phase 1